Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

238 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Levodopa-carbidopa intestinal gel for advanced Parkinson's disease: Impact of LRRK2 and GBA1 mutations.
Thaler A, Anis S, Ponger P, Fay-Karmon T, Livneh V, Faust-Socher A, Greenbaum L, Reiner J, Hilel A, Shabtai H, Alcalay RN, Djaldetti R, Hassin-Baer S, Ezra A, Mirelman A, Giladi N, Gurevich T. Thaler A, et al. Among authors: alcalay rn. Parkinsonism Relat Disord. 2024 Oct;127:107115. doi: 10.1016/j.parkreldis.2024.107115. Epub 2024 Aug 28. Parkinsonism Relat Disord. 2024. PMID: 39208588
Neural correlates of executive functions in healthy G2019S LRRK2 mutation carriers.
Thaler A, Mirelman A, Helmich RC, van Nuenen BF, Rosenberg-Katz K, Gurevich T, Orr-Urtreger A, Marder K, Bressman S, Bloem BR, Giladi N, Hendler T; LRRK2 Ashkenazi Jewish consortium. Thaler A, et al. Cortex. 2013 Oct;49(9):2501-11. doi: 10.1016/j.cortex.2012.12.017. Epub 2013 Jan 7. Cortex. 2013. PMID: 23357204
Fall risk and gait in Parkinson's disease: the role of the LRRK2 G2019S mutation.
Mirelman A, Heman T, Yasinovsky K, Thaler A, Gurevich T, Marder K, Bressman S, Bar-Shira A, Orr-Urtreger A, Giladi N, Hausdorff JM; LRRK2 Ashkenazi Jewish Consortium. Mirelman A, et al. Mov Disord. 2013 Oct;28(12):1683-90. doi: 10.1002/mds.25587. Epub 2013 Oct 7. Mov Disord. 2013. PMID: 24123150
Parkinson disease phenotype in Ashkenazi Jews with and without LRRK2 G2019S mutations.
Alcalay RN, Mirelman A, Saunders-Pullman R, Tang MX, Mejia Santana H, Raymond D, Roos E, Orbe-Reilly M, Gurevich T, Bar Shira A, Gana Weisz M, Yasinovsky K, Zalis M, Thaler A, Deik A, Barrett MJ, Cabassa J, Groves M, Hunt AL, Lubarr N, San Luciano M, Miravite J, Palmese C, Sachdev R, Sarva H, Severt L, Shanker V, Swan MC, Soto-Valencia J, Johannes B, Ortega R, Fahn S, Cote L, Waters C, Mazzoni P, Ford B, Louis E, Levy O, Rosado L, Ruiz D, Dorovski T, Pauciulo M, Nichols W, Orr-Urtreger A, Ozelius L, Clark L, Giladi N, Bressman S, Marder KS. Alcalay RN, et al. Mov Disord. 2013 Dec;28(14):1966-71. doi: 10.1002/mds.25647. Epub 2013 Oct 15. Mov Disord. 2013. PMID: 24243757 Free PMC article.
A voxel-based morphometry and diffusion tensor imaging analysis of asymptomatic Parkinson's disease-related G2019S LRRK2 mutation carriers.
Thaler A, Artzi M, Mirelman A, Jacob Y, Helmich RC, van Nuenen BF, Gurevich T, Orr-Urtreger A, Marder K, Bressman S, Bloem BR, Hendler T, Giladi N, Ben Bashat D; LRRK2 Ashkenazi Jewish Consortium. Thaler A, et al. Mov Disord. 2014 May;29(6):823-7. doi: 10.1002/mds.25827. Epub 2014 Jan 30. Mov Disord. 2014. PMID: 24482120
Michael J. Fox Foundation LRRK2 Consortium: geographical differences in returning genetic research data to study participants.
Alcalay RN, Aasly J, Berg D, Bressman S, Brice A, Brockmann K, Chan P, Clark L, Cormier F, Corvol JC, Durr A, Facheris M, Farrer M, Foroud TM, Gasser T, Giladi N, Halter C, Lang A, Langston JW, Marras C, Marti-Masso JF, Ruiz Martinez J, Mejia-Santana H, Mirelman A, Pont-Sunyer C, Orr-Urtreger A, Raymond D, Saunders-Pullman R, Schüle B, Tanner C, Tolosa E, Urkowitz A, Vilas D, Wise A, Marder K. Alcalay RN, et al. Genet Med. 2014 Aug;16(8):644-5. doi: 10.1038/gim.2014.55. Genet Med. 2014. PMID: 25093570 Free PMC article. No abstract available.
Interest in genetic testing in Ashkenazi Jewish Parkinson's disease patients and their unaffected relatives.
Gupte M, Alcalay RN, Mejia-Santana H, Raymond D, Saunders-Pullman R, Roos E, Orbe-Reily M, Tang MX, Mirelman A, Ozelius L, Orr-Urtreger A, Clark L, Giladi N, Bressman S, Marder K. Gupte M, et al. Among authors: alcalay rn. J Genet Couns. 2015 Apr;24(2):238-46. doi: 10.1007/s10897-014-9756-x. Epub 2014 Aug 17. J Genet Couns. 2015. PMID: 25127731 Free PMC article.
Neuropsychological performance in LRRK2 G2019S carriers with Parkinson's disease.
Alcalay RN, Mejia-Santana H, Mirelman A, Saunders-Pullman R, Raymond D, Palmese C, Caccappolo E, Ozelius L, Orr-Urtreger A, Clark L, Giladi N, Bressman S, Marder K; LRRK2 Ashkenazi Jewish Consortium. Alcalay RN, et al. Parkinsonism Relat Disord. 2015 Feb;21(2):106-10. doi: 10.1016/j.parkreldis.2014.09.033. Epub 2014 Nov 20. Parkinsonism Relat Disord. 2015. PMID: 25434972 Free PMC article.
Olfactory identification in LRRK2 G2019S mutation carriers: a relevant marker?
Saunders-Pullman R, Mirelman A, Wang C, Alcalay RN, San Luciano M, Ortega R, Raymond D, Mejia-Santana H, Ozelius L, Clark L, Orr-Utreger A, Marder K, Giladi N, Bressman SB. Saunders-Pullman R, et al. Among authors: alcalay rn. Ann Clin Transl Neurol. 2014 Sep;1(9):670-8. doi: 10.1002/acn3.95. Epub 2014 Sep 30. Ann Clin Transl Neurol. 2014. PMID: 25493281 Free PMC article.
Nonmotor symptoms in healthy Ashkenazi Jewish carriers of the G2019S mutation in the LRRK2 gene.
Mirelman A, Alcalay RN, Saunders-Pullman R, Yasinovsky K, Thaler A, Gurevich T, Mejia-Santana H, Raymond D, Gana-Weisz M, Bar-Shira A, Ozelius L, Clark L, Orr-Urtreger A, Bressman S, Marder K, Giladi N; LRRK2 AJ consortium. Mirelman A, et al. Among authors: alcalay rn. Mov Disord. 2015 Jun;30(7):981-6. doi: 10.1002/mds.26213. Epub 2015 Mar 21. Mov Disord. 2015. PMID: 25809001 Free PMC article.
238 results